Compare Amphastar Pharmaceuticals Inc (AMPH) vs Avalanche Treasury Corporation Class A Common Stock (AVAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Avalanche Treasury Corporation Class A Common Stock — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Avalanche Treasury Corporation Class A Common Stock trades at $0.34 (market cap $14.82M). The key difference: Amphastar Pharmaceuticals Inc is far larger — about 58.3× Avalanche Treasury Corporation Class A Common Stock's market cap, and Amphastar Pharmaceuticals Inc is trading nearer its 52-week high, Avalanche Treasury Corporation Class A Common Stock nearer its low. Which is the better fit depends on your goals.
| AMPH | AVAT | |
|---|---|---|
Market Cap | $863.95M | $14.82M |
Sector | Health | Financials |
52-Week High | $30.81 | $10.75 |
52-Week Low | $16.87 | $0.30 |
Enterprise Value | $1.26B | $14.82M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
AVAT trades at $0.33, down 4.35% on the day, with a bearish technical signal from moving averages. The company reported a net income of $8.28 million for 2025, yet shows negative operating cash flow of -$930,710. Recent news highlights its Nasdaq listing, positioning it as an operating company focused on capital allocation within its ecosystem, attracting attention from major financial media.
The outlook is mixed; low P/E of 12 and P/B of 0.4 suggest undervaluation, but negative cash flow and ROA of -7.25% raise sustainability concerns. Risks include execution challenges in capital deployment and market volatility, while institutional interest may grow post-listing, offering potential upside if operational metrics improve.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Avalanche Treasury Corporation Class A Common Stock
Avalanche Treasury Corp operates as a digital asset treasury company focused on holding and managing digital asset investments. The company was founded on September 22, 2025, and is headquartered in New York, NY.
Read more on AVAT →
